---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-036706"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:45:01.825327+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine reports Q3 net loss of $50.7M, cash runway through end 2024; provides pipeline updates

## Summary
- R&D expenses $41.0M (up 64% YoY); G&A $10.5M (up 59%); net loss widened to $50.7M from $29.4M.
- Cash, equivalents, and investments $178.8M as of Sept 30, 2023, down from $307.4M at Dec 31, 2022.
- FDA granted Rare Pediatric Drug designation for PM359 (CGD); IND-enabling studies started, IND filing planned for 2024.
- Preclinical data showed up to 50% liver editing in NHPs for GSD1b and up to 70% correction in photoreceptors for retinitis pigmentosa.
- U.S. PTO issued third patent covering Prime Editing systems with PEgRNA, Prime Editor protein, and optionally a recombinase.

## SEC filing metadata
- accession: 0001628280-23-036706
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828023036706/0001628280-23-036706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828023036706/prme-20231103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-036706
- JSON: https://secwatch.observer/filing/0001628280-23-036706.json
- Plain text: https://secwatch.observer/filing/0001628280-23-036706.txt

## Key facts
- Earnings Releases
  Prime Medicine, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 3, 2023, Prime Medicine, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000162828023036706/0001628280-23-036706-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.